Given the approximately 75 million Americans who are heterozygous for the ApoE ε4 allele, and the approximately seven million Americans who are homozygous, early identification and treatment (presymptomatic or symptomatic) could potentially have a major impact on the prevalence of Alzheimer's disease-mediated cognitive decline. The gene discussed is APOE; the disease is Mental deterioration.